Cargando…

Effects of door‐to‐tolvaptan time on short‐term clinical outcome in patients with acute heart failure

AIMS: We investigated the effects of door‐to‐tolvaptan (D2T) time on short‐term urine volume and in‐hospital clinical outcomes in patients with acute heart failure (AHF). METHODS AND RESULTS: Patients with AHF, treated with tolvaptan at two hospitals, were enrolled in this retrospective observationa...

Descripción completa

Detalles Bibliográficos
Autores principales: Nomura, Ryohei, Morishita, Tetsuji, Sato, Yusuke, Aoyama, Daisetu, Shimizu, Tomohiro, Uzui, Hiroyasu, Nakano, Akira, Tada, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10682855/
https://www.ncbi.nlm.nih.gov/pubmed/37752742
http://dx.doi.org/10.1002/ehf2.14530
_version_ 1785151066500759552
author Nomura, Ryohei
Morishita, Tetsuji
Sato, Yusuke
Aoyama, Daisetu
Shimizu, Tomohiro
Uzui, Hiroyasu
Nakano, Akira
Tada, Hiroshi
author_facet Nomura, Ryohei
Morishita, Tetsuji
Sato, Yusuke
Aoyama, Daisetu
Shimizu, Tomohiro
Uzui, Hiroyasu
Nakano, Akira
Tada, Hiroshi
author_sort Nomura, Ryohei
collection PubMed
description AIMS: We investigated the effects of door‐to‐tolvaptan (D2T) time on short‐term urine volume and in‐hospital clinical outcomes in patients with acute heart failure (AHF). METHODS AND RESULTS: Patients with AHF, treated with tolvaptan at two hospitals, were enrolled in this retrospective observational study. The D2T time was defined as the time elapsed from the arrival of a patient at a participating hospital to the first administration of tolvaptan. The group with the D2T time within 6 h was defined as the ‘early group’. The primary outcome was 48‐h urine volume. The secondary outcomes were in‐hospital death, length of hospital stay, and worsening renal function (WRF) incidence. A restricted cubic spline model was used to evaluate the presence of a nonlinear association between the D2T time and 48‐h urine volume and the odds ratio of WRF incidence. Our study included a total of 138 patients with AHF who were started on tolvaptan after hospitalization. The median D2T time was 5.3 h (interquartile range: 3.0–31.9 h). Seventy‐four patients (53.6%) were classified to be in the early group. Baseline characteristics were similar in the two groups: mean age (85.4 ± 9.6 years vs. 84.5 ± 9.5 years; P = 0.59) and male sex (n = 22 [33.3%] vs. n = 29 [46%]; P = 0.16), except that patients in the early group had higher systolic blood pressure than those in the delayed group (138.2 ± 22.9 vs. 125.7 ± 21.7; P = 0.001). The initial tolvaptan dose in the delayed group was much lower than that in the early group (7.5 [7.5, 7.5] vs. 7.5 [5.6, 7.5] mg; P = 0.01). Total urine volume in 48 h did not differ in the early and delayed groups (4113 ± 1758 mL vs. 4201 ± 1893 mL; P = 0.80). The relationship between D2T time and total urine volume within 48 h increased slightly, with a peak at a D2T time of 15 h, and gradually decreased, thereafter. In‐hospital death and the length of hospital stay did not differ significantly between the two groups (n = 1, 1.3% vs. n = 4, 6.3%; P = 0.18, and 5.0 [12.0, 30.0] vs. 22.0 [14.5, 30.0] days; P = 0.17, respectively). Notably, the restricted cubic spline model for the odds ratio of WRF incidence increased as the D2T time was delayed (P for effect<0.01). CONCLUSIONS: The shorter D2T time did not affect the short‐term urine volume and in‐hospital outcomes but reduced the risk of WRF incidence in patients with AHF.
format Online
Article
Text
id pubmed-10682855
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-106828552023-11-30 Effects of door‐to‐tolvaptan time on short‐term clinical outcome in patients with acute heart failure Nomura, Ryohei Morishita, Tetsuji Sato, Yusuke Aoyama, Daisetu Shimizu, Tomohiro Uzui, Hiroyasu Nakano, Akira Tada, Hiroshi ESC Heart Fail Original Articles AIMS: We investigated the effects of door‐to‐tolvaptan (D2T) time on short‐term urine volume and in‐hospital clinical outcomes in patients with acute heart failure (AHF). METHODS AND RESULTS: Patients with AHF, treated with tolvaptan at two hospitals, were enrolled in this retrospective observational study. The D2T time was defined as the time elapsed from the arrival of a patient at a participating hospital to the first administration of tolvaptan. The group with the D2T time within 6 h was defined as the ‘early group’. The primary outcome was 48‐h urine volume. The secondary outcomes were in‐hospital death, length of hospital stay, and worsening renal function (WRF) incidence. A restricted cubic spline model was used to evaluate the presence of a nonlinear association between the D2T time and 48‐h urine volume and the odds ratio of WRF incidence. Our study included a total of 138 patients with AHF who were started on tolvaptan after hospitalization. The median D2T time was 5.3 h (interquartile range: 3.0–31.9 h). Seventy‐four patients (53.6%) were classified to be in the early group. Baseline characteristics were similar in the two groups: mean age (85.4 ± 9.6 years vs. 84.5 ± 9.5 years; P = 0.59) and male sex (n = 22 [33.3%] vs. n = 29 [46%]; P = 0.16), except that patients in the early group had higher systolic blood pressure than those in the delayed group (138.2 ± 22.9 vs. 125.7 ± 21.7; P = 0.001). The initial tolvaptan dose in the delayed group was much lower than that in the early group (7.5 [7.5, 7.5] vs. 7.5 [5.6, 7.5] mg; P = 0.01). Total urine volume in 48 h did not differ in the early and delayed groups (4113 ± 1758 mL vs. 4201 ± 1893 mL; P = 0.80). The relationship between D2T time and total urine volume within 48 h increased slightly, with a peak at a D2T time of 15 h, and gradually decreased, thereafter. In‐hospital death and the length of hospital stay did not differ significantly between the two groups (n = 1, 1.3% vs. n = 4, 6.3%; P = 0.18, and 5.0 [12.0, 30.0] vs. 22.0 [14.5, 30.0] days; P = 0.17, respectively). Notably, the restricted cubic spline model for the odds ratio of WRF incidence increased as the D2T time was delayed (P for effect<0.01). CONCLUSIONS: The shorter D2T time did not affect the short‐term urine volume and in‐hospital outcomes but reduced the risk of WRF incidence in patients with AHF. John Wiley and Sons Inc. 2023-09-26 /pmc/articles/PMC10682855/ /pubmed/37752742 http://dx.doi.org/10.1002/ehf2.14530 Text en © 2023 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Articles
Nomura, Ryohei
Morishita, Tetsuji
Sato, Yusuke
Aoyama, Daisetu
Shimizu, Tomohiro
Uzui, Hiroyasu
Nakano, Akira
Tada, Hiroshi
Effects of door‐to‐tolvaptan time on short‐term clinical outcome in patients with acute heart failure
title Effects of door‐to‐tolvaptan time on short‐term clinical outcome in patients with acute heart failure
title_full Effects of door‐to‐tolvaptan time on short‐term clinical outcome in patients with acute heart failure
title_fullStr Effects of door‐to‐tolvaptan time on short‐term clinical outcome in patients with acute heart failure
title_full_unstemmed Effects of door‐to‐tolvaptan time on short‐term clinical outcome in patients with acute heart failure
title_short Effects of door‐to‐tolvaptan time on short‐term clinical outcome in patients with acute heart failure
title_sort effects of door‐to‐tolvaptan time on short‐term clinical outcome in patients with acute heart failure
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10682855/
https://www.ncbi.nlm.nih.gov/pubmed/37752742
http://dx.doi.org/10.1002/ehf2.14530
work_keys_str_mv AT nomuraryohei effectsofdoortotolvaptantimeonshorttermclinicaloutcomeinpatientswithacuteheartfailure
AT morishitatetsuji effectsofdoortotolvaptantimeonshorttermclinicaloutcomeinpatientswithacuteheartfailure
AT satoyusuke effectsofdoortotolvaptantimeonshorttermclinicaloutcomeinpatientswithacuteheartfailure
AT aoyamadaisetu effectsofdoortotolvaptantimeonshorttermclinicaloutcomeinpatientswithacuteheartfailure
AT shimizutomohiro effectsofdoortotolvaptantimeonshorttermclinicaloutcomeinpatientswithacuteheartfailure
AT uzuihiroyasu effectsofdoortotolvaptantimeonshorttermclinicaloutcomeinpatientswithacuteheartfailure
AT nakanoakira effectsofdoortotolvaptantimeonshorttermclinicaloutcomeinpatientswithacuteheartfailure
AT tadahiroshi effectsofdoortotolvaptantimeonshorttermclinicaloutcomeinpatientswithacuteheartfailure